MARKET

OSMT

OSMT

Osmotica Pharmaceuticals Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.25
+0.30
+6.06%
After Hours: 5.25 0 0.00% 16:00 09/25 EDT
OPEN
4.970
PREV CLOSE
4.950
HIGH
5.31
LOW
4.925
VOLUME
304.54K
TURNOVER
--
52 WEEK HIGH
9.67
52 WEEK LOW
2.810
MARKET CAP
334.86M
P/E (TTM)
-1.7892
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Osmotica to Present at 2020 Wells Fargo Virtual Healthcare Conference
BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at
GlobeNewswire · 09/02 20:30
Osmotica Pharmaceuticals plc's (NASDAQ:OSMT) Path To Profitability
Simply Wall St. · 08/20 19:30
Osmotica Pharmaceuticals Q2 EPS $(0.22) Misses $(0.12) Estimate, Sales $37.53M Miss $40.83M Estimate
Osmotica Pharmaceuticals (NASDAQ:OSMT) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.12) by 83.33 percent. This is a 650 percent decrease over earnings of $0.04 per
Benzinga · 08/11 20:21
Osmotica Pharmaceuticals plc to Provide Second Quarter 2020 Business and Financial Update and Presentation on Upneeq™ on August 11, 2020
-Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO-BRIDGEWATER, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutica
GlobeNewswire · 08/07 00:00
Osmotica out-licenses droopy eyelid med to Santen Pharma
Seeking Alpha · 07/28 11:03
Santen And RVL Pharmaceuticals, Inc., an Osmotica Company, Enter Exclusive License Agreement In Japan, Asia, And EMEA For RVL-1201 Treatment For Acquired Blepharoptosis; Osmotica To Receive Up To $89M In Upfront And Milestone Payments
OSAKA, Japan and BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd (hereinafter, Santen) and RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (NASDAQ:OSMT)
Benzinga · 07/28 10:53
Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201, a First-in-Class Treatment for Acquired Blepharoptosis
OSAKA, Japan and BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd (hereinafter, Santen) and RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (hereinafter, Osmotica), announced today an ex
GlobeNewswire · 07/28 10:50
FDA sets action date for Osmotica's Arbaclofen
Seeking Alpha - Article · 07/20 15:10
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OSMT. Analyze the recent business situations of Osmotica Pharmaceuticals Plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OSMT stock price target is 9.33 with a high estimate of 12.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 82
Institutional Holdings: 6.17M
% Owned: 9.67%
Shares Outstanding: 63.78M
TypeInstitutionsShares
Increased
26
512.37K
New
25
-72.56K
Decreased
16
1.73M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.88%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Chief Executive Officer/Director
Brian Markison
Chief Financial Officer
Andrew Einhorn
Chief Operating Officer/Executive Vice President
James Schaub
Executive Vice President
Tina deVries
General Counsel/Secretary
Christopher Klein
Director
Joachim Benes
Director
David Burgstahler
Director
Sriram Venkataraman
Director
Juan Vergez
Independent Director
Gregory Cowan
Independent Director
Michael DeBiasi
Independent Director
Fred Weiss
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OSMT
Osmotica Pharmaceuticals plc is an integrated biopharmaceutical company. The Company is focused on the developing and commercialization of specialty products that target markets with underserved patient populations. The Company is focused on progressing Phase III candidates under clinical development Ontinua ER and RVL-1201. It has developed Ontinua ER using its proprietary Osmodex drug delivery system. Ontinua ER has been designated by the FDA as an Orphan Drug in this indication. The Company is conducting a second Phase III clinical trial of RVL-1201 for droopy eyelid. The Company’s promoted products include specialty neurology drugs, such as Lorzone and ConZip for pain management, as well as women's health products, such as Divigel for menopause and the OB Complete family of prescription prenatal dietary supplements. The Company’s non-promoted products portfolio include methylphenidate ER and VERT as well as smaller volume ANDAs and prescription dietary supplements.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Osmotica Pharmaceuticals PLC stock information, including NASDAQ:OSMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OSMT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OSMT stock methods without spending real money on the virtual paper trading platform.